ClinicalTrials.gg
TerminatedNCT07556757Updated Aug 19, 2026

A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia

A Phase 1 interventional study of CD19 t-haNK in B-ALL and Leukemia, sponsored by ImmunityBio, Inc.. Terminated at 2 sites in South Africa. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by ImmunityBio, Inc. · Phase 1, Interventional, and Treatment

Why this study was terminated
Study was terminated prematurely by the Sponsor for reasons not related to the safety of study drug

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Apr 2025, registered Jul 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 13 studies in Leukemia with a site in South Africa — none open to participants now, 2 under way, 2 of them phase 3. Leukemia · South Africa.

Enrollment
10th of 10
4 · median 408
Started
2025
the only one that year
Phase 1
Only one
of the 13
Registered
13th of 13
by date
Lead sponsor
1 of 13
ImmunityBio, Inc.

Among the 13 studies in Leukemia with a site in South Africa, this one is the 10th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2025, is the only one in phase 1, and was the 13th registered.

Leukemia

2,382 studies on the registry are indexed under Leukemia; 254 are open to participants now.

Browse Leukemia studies →

Open to participants now

None of the 13 studies in Leukemia with a site in South Africa is open now. The open studies under Leukemia, anywhere →

Who these studies take

Of the 208 Leukemia studies recruiting now, 112 (54%) set no upper age limit and 74 (36%) stop at 75 or younger; 86 take children under 18; 24 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Leukemia with a site in South Africa as a file.
02

Study summary

This is a phase 1, open-label study to evaluate the safety and efficacy of CD19 t-haNK in patients with B-cell acute lymphoblastic leukemia. Up to 10 patients will receive at least 1 dose of study drug.

Read the detailed description

Up to 20 participants may be screened to enroll up to 10 patients who will receive at least 1 dose of study drug. The initial three participants will receive study drug in a staggered fashion, with a 7-day interval between each participant to evaluate the safety profile of the investigational product.

Patients will receive two 4-week cycles of IV CD19 t-haNK IV as a single agent regimen. Following a 1-week safety pause, patients will then receive 1 additional cycle of CD19 t-haNK given twice a week on an outpatient basis. Patients with no evidence of disease progression may be eligible to receive 2 additional cycles of treatment. Bone marrow aspirate will be performed for bone marrow analysis on day 22( +/- 3 days), and every 8 weeks( +/-1 week) thereafter. If there is no evidence of abnormal blasts present in bone marrow, measurable residual( MRD) testing will be performed. Treatment will be discontinued if a participant has confirmed progressive disease or unacceptable toxicity. Safety will be assessed for all participants.

03

Conditions studied

  • B-ALL
  • Leukemia

Browse trials for

Keywords

  • B-Cell
  • Acute
  • Lymphoblastic
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 12 years old.
  2. Able to understand and provide a signed that fulfills the relevant Human Research Ethics Committee (HREC) or Independent Ethics Committee (IEC) guidelines.
  3. Histologically or flow cytometry documented pre B-ALL.
  4. after achieving a 2nd complete remission (CR) or failed one cycle of re-induction therapy or with MRD positivity after ≥ 2 cycles of induction.
  5. Must be willing to undergo a lumbar puncture (LP) for CSF analysis and administration of IT chemotherapy.
  6. Performance status: Lansky score >60%, for participant ≥12 to \<16 years. (ECOG) score of ≤ 1 for participants ≥ 16 years.
  7. Expected survival > 16 weeks.
  8. Stated willingness to comply with study procedures.
  9. Able to attend required study visits and return for adequate follow-up, as required by this protocol.
  10. Agreement to practice effective for female participants of and nonsterile males. Female participants of childbearing potential must agree to use effective contraception while on study and for at least 30 days after the last dose of study drug. Nonsterile male participants must agree to use a condom while on study and for up to 5 months after the last dose of study drug. Effective contraception includes orals, injectables, surgical sterilization (eg, vasectomy, tubal ligation), two forms of barrier methods (eg, condom, diaphragm), and implants such as intrauterine devices (IUDs).

All inclusion criteria must be answered "yes" for a participant to participate in the trial.

Exclusion criteria

Exclusion Criteria:

  1. Participants with T-cell leukaemia and Burkitt's M3 leukaemia.
  2. Known or allergy to any component of the study medication(s), including sulfa-containing (eg, dimethyl sulfoxide, DMSO).
  3. Inadequate organ function, evidenced by the following laboratory results:

    1. Serum creatinine ≥ 2 mg/dL
    2. (AST) / Alanine aminotransferase (ALT) ≥ 5 (ULN)
    3. Total ≥ 2 mg/dL
  4. Serious uncontrolled concomitant disease that would contraindicate the use of the drug used in this study or that would put the participant at high risk for treatment related complications.
  5. History of significant disease OR active, uncontrolled autoimmune phenomenon: such as systemic lupus erythematous, Wegner's glomerulonephritis, autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura requiring therapy defined as > 20 mg of prednisone or equivalent daily.
  6. History of hematopoietic stem-cell transplantation (HSCT) requiring ongoing systemic (GvHD) therapy.
  7. History of receiving allograft organ transplant requiring .
  8. Participants post solid organ transplant who develop high grade lymphomas or leukaemias.
  9. Nonmalignant CNS disease (eg, stroke, epilepsy, vasculitis, or neurodegenerative disease).
  10. History of or active inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis).
  11. Uncontrolled hypertension (systolic > 160 mm Hg and/or diastolic > 110 mm Hg) or (ie, active) cardiovascular disease, cerebrovascular accident/stroke, or myocardial infarction within 6 months prior to first study medication; unstable angina; congestive heart failure of Class 2 or higher; or serious cardiac arrhythmia requiring medication.
  12. Current chronic daily treatment (continuous for > 3 months) with systemic corticosteroids defined as > 20 mg of prednisone or equivalent daily, excluding inhaled steroids. Short-term steroid use to prevent IV contrast allergic reaction or anaphylaxis in participants who have known contrast allergies is allowed.
  13. Currently taking any medication(s) (herbal or prescribed) known to have an adverse drug reaction with any of the study medications.
  14. History of (HIV) with current \< 350 cells/μL and a detectable HIV viral load.
  15. Known carriers of virus (HBV) infection that is currently hepatitis B surface antigen (HBsAg) positive.
  16. Concurrent active other than basal or squamous cell carcinomas of the skin.
  17. Assessed by the Investigator to be unable or unwilling to comply with the requirements of the protocol.
  18. Women who are pregnant or breastfeeding.

All exclusion criteria must be answered "no" for a participant to participate in the trial.

Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    CD19 t-haNK Arm

    IV infusion of CD19 t-haNK

    Drug: CD19 t-haNK

Interventions

  • DrugCD19 t-haNK

    IV infusion of CD19 t-haNK

06

What researchers measure

Primary outcomes

  1. Evaluate safety of CD19 t-haNK as a single agent in participants with selected CD19+ relapsed B-ALL.

    Incidence of TEAEs and SAEs graded using the NCI CTCAE Version 5.0 and clinically important changes in safety laboratory tests and vital signs.

    Time frame: up to 12 months post last dose of study drug

Secondary outcomes

  1. Obtain preliminary estimates of efficacy of CD19 t-haNK in terms of bone marrow response.

    Bone marrow aspirate will be performed for bone marrow analysis on Day 22 (±3 days), and every 8 weeks (±1 week) thereafter.

    Time frame: up to 12 months post last dose of study drug

  2. Obtain preliminary estimates of efficacy of CD19 t-haNK in terms of overall survival (OS)

    OS will be evaluated using Kaplan-Meier methods. OS will be defined as the time from the date of first treatment to the date of death (any cause).

    Time frame: up to 12 months post last dose of study drug

07

Study locations

2 sites
  • Dr Jackie Thomson Inc
    Johannesburg, 2193, South Africa
  • Alberts Cellular Therapy
    Pretoria, 0044, South Africa
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2025 to primary completion in Jul 2026, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2025
First posted
Apr 29, 2026
StartActual
Apr 11, 2025
Primary completionActual
Jul 1, 2026
CompletionActual
Jul 1, 2026
Last update
Aug 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07556757
Lead sponsor
ImmunityBio, Inc.
Responsible party
Sponsor
First posted
Apr 29, 2026
Start date
Apr 11, 2025
Primary completion
Jul 1, 2026
Completion
Jul 1, 2026
Last update
Aug 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion